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Abstract
Progression of glioma is associated with local degenerative processes which are attributed to the activity of gelatinases.
As glioma cells are candidate for secretion of these enzymes, we have studied in vitro the potential of cytokines
  .  .  ..interleukin-1a IL-1 , tumor necrosis factor-alpha TNFa and transforming growth factor-beta TGFb to regulate the2
 .  .  .expression of gelatinase A and B Gels A and B, respectively in two glioma cells of human A172 and rat origin C6 . We
showed that IL-1 and TNFa both induced gene expression and protein secretion of Gel B in both cell lines, as revealed by
RT-PCR and gelatin zymography, respectively. In C6 cells, TNFa had no effect on Gel A constitutive expression while
IL-1 increased its production, but only at high doses. We have also demonstrated that TGFb inhibited both IL-1- or2
TNFa-induced gene expression and Gel B production in a dose-dependent manner but had no effect on Gel A secretion. The
 .effect of TGFb on Gel B secretion was reversed by phorbol myristate acetate PMA . Taken together, these data suggest2
that IL-1, TNFa and TGFb tightly regulate Gel B secretion in glioma cells, an enzyme which is believed to play an2
important role in the local invasion of brain tissue by tumor cells. q 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
Glioblastomas constitute 15–25% of all intracra-
nial tumors and about 50% of all glioma. Their
Abbreviations: ECM: extracellular matrix; Gel A: gelatinase
A; Gel B: gelatinase B; IL-1: interleukin-1; LPS: lipopolysaccha-
ride; MMP: matrix metalloproteinase; PKC: protein kinase C;
PMA: phorbol 12-myristate 13-acetate; TGFb : transforming
growth factor-beta; TIE: transforming growth factor-beta in-
hibitory element; TIMP: tissue inhibitor of metalloproteinase;
TNFa : tumor necrosis factor-alpha
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prognosis is poor and the rapid growth and local
invasive potential of these tumors is frequently asso-
ciated with the remodeling of the extracellular matrix
 .ECM at the tumor site. The degradation of ECM
macromolecules not only allow glioma cells to in-
vade the surrounding tissues but can also cause a
disregulation of growth and differentiation of the
malignant glioma cells. For instance, decreased cellu-
lar proliferation, stellate cell formation and increased
levels of a marker of differentiation are observed
upon contact of glioma cells with type I and IV
w xcollagen in vitro 1 .
The ability of tumor cells to migrate through the
ECM has been partly attributed to their secretion of
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 .matrix metalloproteinases MMPs . MMPs are mem-
bers of a family of Zn2q- and Ca2q-dependent prote-
olytic enzymes that possess substrate affinities for
components of the ECM, namely type IV collagen,
fibronectin and proteoglycans. All of these enzymes,
secreted in latent inactive form, require activation by
other MMPs or by serine proteases. The expression
of several of the MMPs, along with that of tissue
 .inhibitors of metalloproteinase TIMPs , has been
shown to be tightly regulated by exposure to soluble
factors, such as tumor promoters, cytokines, and
 w x.growth factors reviewed in Ref. 2 . Accordingly,
 .Fig. 1. Gelatinase secretion in supernatants of glioma cell stimulated with IL-1 and TNFa . Rat C6 cells a were treated for 18 h with or
 .  .  .  .without NS , murine IL-1 100 Urml or murine TNFa 100 Urml . LPS 100 ngrml was used as a positive control for C6 cells.
 .  .  .  .Human A172 cells b were stimulated with or without NS human IL-1 100 Urml or human TNFa 1000 Urml . Supernatants were
 .collected, lyophilized and assayed for their gelatinase content by zymography and imaging densitometry c–d . Molecular weight markers
 .kDa appear on the left. Errors bars represent the standard error of the mean of triplicates. Results are representative of three independent
experiments. ) PF0.05.
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remodeling, as well as maintenance of the integrity of
ECM are the results of a delicate balance of MMPs
and TIMPs production.
 .Gelatinases of type A Gel A: MMP-2; 72 kDa
 .and B Gel B: MMP-9; 92 kDa are two members of
the MMP family. They have recently received close
attention since their increased production appeared to
correlate with the malignant potential of several types
w xof cancer, including human gliomas 3,4 . The in-
crease of gelatinases is largely attributed to the capac-
ity of tumor cells to secrete these MMPs. Glioma cell
lines secrete constitutively Gel A. Exposure of a
number of cell lines to phorbol 12-myristate 13-
 .acetate PMA , a classical tumor promoter, generally
w xinduces Gel B expression 5,6 . This increased ex-
pression of Gel B is often associated with low levels
of TIMPs and seems to correlate with in vitro inva-
w xsive properties of glioma cells 7 .
Since Gel B seems to be involved not only in
invasion of tumor cells but also in neuropathological
w xdiseases such as nerve demyelinization 8 and
w xblood–brain barrier degradation 9 , two common
features of gliomas, understanding its regulation by
physiological factors is generating a great deal of
 .  .Fig. 2. Dose-dependent a and b and additive e effects of IL-1 and TNFa on gelatinase secretion by C6 cells. C6 cells were treated for
 .18 h with or without NS the indicated concentrations of IL-1 or TNFa . Supernatants were collected, lyophilized and assayed for their
 .  .gelatinase content by zymography and imaging densitometry c–d . Hatched bars, Gel B; filled bars, Gel A. Zymography e and
 .  . densitometry analysis f represent the additive effect on gelatinase secretion by C6 cells treated with IL-1 100 Urml , TNFa 100
.Urml and IL-1qTNFa . Error bars represent the standard error of the mean of quadruplicates. Results are representative of three
independent experiments. Multiple regression analysis showed no significant differences between S IL-1qTNFa and S IL-1qS TNFa .
) PF0.05.
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 .Fig. 2 continued .
w xinterest. Recently, Rao et al. 10 showed that Gel B
gene expression was upregulated in malignant gliomas
and that this upregulation correlated with the malig-
nant progression of human glioma in vivo. As one of
the key features of glioma cells is their ability to
secrete inflammatory cytokines like IL-1, TNFa , and
w ximmunosuppressive cytokines like TGFb 11,12 ,2
we have studied in vitro the regulation of Gel B
secretion by these cytokines in human and rat glioma
cell lines.
Our results show that exposure of glioma cells to
IL-1 or TNFa induced de novo gene expression and
protein secretion of Gel B in both rat and human
glioma cell lines. In C6 rat glioma cells, expression
of Gel B by IL-1 and TNFa was dose-dependent,
and when added together, had an additive effect.
High doses of IL-1, but not TNFa , increased the
constitutive expression of Gel A. Furthermore, the
production of Gel B, but not Gel A, was down-regu-
lated by TGFb . This inhibition by TGFb was also2 2
observed at the Gel B transcriptional level. Taken
together, these data suggest that production of Gel B
in glioma cells is tightly regulated by IL-1, TNFa
and TGFb and that in vivo expression of these2
MMP may depend on the in situ balance between
cytokines secreted by glioma and immune infiltrating
cells.
2. Material and methods
2.1. Reagents
 .LPS Escherichia coli, strain 0127:B8 , gelatin
 . wtype A, from porcine skin , PMA and 3- 4,5-Di-
xmethylthyazol-2-yl -2,5,diphenyltetrazolium bromide
 . MTT were obtained from Sigma St. Louis, MO,
.USA . Tissue culture reagents were obtained from
 .Gibco BRL Grand Island, NY, USA . Recombinant
 .mouse and human interleukin-1a IL-1 , tumor
 .necrosis factor-a TNFa and recombinant human
 .transforming growth factor-2 TGFb were pur-2
 .chased from Genzyme Cambridge, MA, USA . All
the cytokines used are active on rat cells.
2.2. Cell cultures and treatments
C6 and A172 glioma cell lines were obtained from
the American Type Culture Collection Rockville,
.MD, USA . C6 cells were grown in Ham’s F10
 .medium supplemented with 15% vrv horse serum,
 .2.5% vrv FBS and 10 mM HEPES buffer. A172
cells were grown in Dulbecco’s modified Eagle
 .medium supplemented with 10% vrv FBS, 10 mM
 .HEPES buffer, penicillin 100 Urml , streptomycin
 .  .100 mgrml and fungizone 0.25 mgrml . Routine
testing showed the cells to be free of mycoplasma.
For stimulation assays, cells were trypsinized with a
 .solution of 1 mM EDTAr0.25% wrv trypsin,
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seeded at a density of 1=105 cellsrml in 24-well
cluster plates, and incubated for 18 h at 378C in 5%
CO . Monolayers were then washed three times with2
 .phosphate buffer saline PBS and fresh serum-free
media, containing the appropriate stimulants, was
added at the indicated concentration. Unless other-
wise indicated, supernatants were harvested after 18 h
of stimulation and stored at y208C until assayed.
The remaining cells were tested by the MTT assay to
ensure that none of the stimulants used affected cell
 .proliferation data not shown . All experimental val-
ues represent the mean of triplicates or quadruplicates
and are representative of at least three independent
experiments.
2.3. Detection of gelatinase secretion
Gelatinase secretion of cell culture supernatants
was determined by SDSrPAGE zymography using
w xgelatin as substrate, as previously described 13 .
 .Briefly, samples 100 ml were lyophilized, resus-
pended in loading buffer and, without prior denatura-
tion, were run on a 7.5% SDS-polyacrylamide gel
containing 1 mgrml of gelatin. After electrophoresis,
gels were washed to remove SDS and incubated for
18 h at 378C in a renaturing buffer 50 mM Tris, 5
.mM CaCl , 0.02% NaN , 1% Triton X-100 . Gels2 3
were subsequently stained with Coomassie brilliant
blue G-250 and destained in 30% methanolr10%
 .acetic acid vrv to detect gelatinase secretion. Den-
sitometric values of negatively stained bands were
obtained through computerized image analysis Bio-
Rad, model GS-670 Densitometer, Mississauga, On-
.tario, Canada . Results are expressed as arbitrary
scanning units.
2.4. Determination of gelatinase B mRNA le˝els
Isolation of total cellular RNA from the C6 cells
was performed by centrifugation on CsCl gradient
w x14 ; 2 mg of total RNA were used for first strand
cDNA synthesis using Moloney murine leukemia
virus reverse transcriptase Boerhinger Mannheim,
.Laval, Que, Canada following the manufacturer’s
protocol. Primers pairs for murine Gel B-specific
amplification of cDNA PCR Core Kit, Boerhinger
.  X . XMannheim were as follows: 5 primer 5 -
CATGCGGCCGCCATGAGTCCCTGGCAG-3X and
 X . X3 primer 5 -TTGGATCCAGTATGTGATGT-
TATGATG-3X. These primers amplify a 380-bp se-
quence located at position 1-380 of the rat Gel B
w xmRNA sequence 15 . Gel B-specific competitor
cDNA PCR MIMIC Kit; Clontech Laboratories, Palo
.Alto, CA, USA was used at the following concentra-
tions: 100, 10, 1, 0.1 and 0.01 amolrreaction mix-
 .ture. The control mouse b-actin cDNA 514 bp was
amplified using the primers Stratagene, La Jolla,
.  X . XCA, USA : 5 primer 5 -TGTGATGGTGG-
X  X . XGAATGGGTCAG-3 and 3 primer 5 -TT-
TGATGTCACGCACGATTTCC-3X. PCR was per-
formed on a MJ Research Thermal Cycler Model
.PTC-100e; Watertown, MA, USA using the follow-
ing program: step 1, 948Cr1 min; step 2, 588Cr2
min; step 3, 728Cr3 min for 30 cycles. PCR products
 6 .  .Fig. 3. Induction of Gel B mRNA by IL-1 and TNFa . C6 cells 5=10 cellsrml were stimulated for 18 h with or without NS , LPS
 .  .  .100 ngrml , IL-1 100 Urml or TNFa 100 Urml . Total RNA was isolated and used for competitive PCR using Gel B primers.
Molecular weight markers are 1 kb ladder.
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were visualized on 1.5% agarose gels staining by
ethidium bromide. The Gel Brcompetitor ratio was
determined by densitometric analysis.
2.5. Statistical analysis
Statistical comparisons between means were per-
w xformed using Tukey’s test 16 . For dose–response
and additive effects, multiple regression analysis were
used.
3. Results
3.1. Effects of IL-1 and TNFa on gelatinase secretion
Rat C6 and human A172 glioma cell lines were
treated for 18 h with IL-1 or TNFa ; LPS was used as
a positive control in C6 cells. Zymographic analysis
showed that culture supernatants from IL-1 or
TNFa-treated cells had a significant increase in
gelatinase secretion when compared to untreated cells.
This increase was located at a molecular weight 94
.kDa corresponding to the molecular weight of the
 .precursor form of Gel B Fig. 1 . A low constitutive
level of Gel B production was found in A172 cells
but not in C6 cells. Lower molecular weight bands
corresponded to the active forms of Gel B 86 to 82
.kDa . Addition to the zymogram of 1–10 phenanthro-
line or EDTA, two MMP specific inhibitors, abol-
 .ished enzymatic activity data not shown , confirming
that the gelatinolytic activity of the samples was due
to metalloproteinase activity. Induction of the 94-kDa
Gel B by IL-1 or TNFa was dose-dependent Fig. 2a
.and b; PF0.0001 . IL-1 was found to be a more
potent inducer of the 94-kDa Gel B secretion than
 . TNFa Fig. 2c . When added together, IL-1 100
.  .Urml and TNFa 100 Urml , or at other concentra-
 .tions data not shown , had an additive but not syner-
 .gistic effect on Gel B secretion Fig. 2e; Ps0.29 .
 .In contrast to Gel B, the secretion of latent 66 kDa
 .and active forms 62 to 58 kDa of Gel A by C6 and
 w x.A172 cells was constitutive Fig. 1a and b; 17 .
 .High doses of IL-1, but not TNFa Fig. 2e; Ps0.18 ,
significantly increased Gel A production by C6 cells
 .Fig. 2d; Ps0.02 .
3.2. Induction of Gel B gene expression by IL-1 and
TNFa in C6 cell line
The effect of IL-1 and TNFa on mRNA levels of
Gel B from C6 cells was determined by quantitative
reverse transcription PCR, using Gel B primers and
 .competitor cDNA at different concentrations Fig. 3 .
A PCR product corresponding to Gel B message was
induced by both IL-1 and TNFa , demonstrating that
the 94-kDa gelatinase secretion detected in culture
supernatants corresponded to Gel B and confirming
the absence of Gel B in untreated C6 cells. These
results indicate that Gel B expression is transcription-
ally regulated by both cytokines in glioma cells.
3.3. Inhibition of Gel B secretion and gene expres-
sion of C6 cells by TGFb2
Previous studies have shown that TGFb can up-
regulate the production of Gel B in human fibroblasts
 w x.and keratinocytes reviewed in Ref. 18 . Since
glioma cells secrete TGFb and express its receptor2
w x19 , we have studied the regulatory effect of TGFb2
on Gel B secretion. TGFb alone had no effect on2
Gel B production; however, when added together
 .  .with IL-1 Fig. 4a or TNFa Fig. 4b , a significant
dose-dependent inhibition of Gel B secretion was
 .observed up to 70%; Fig. 4; PF0.0001 . Inhibition
curves for IL-1 and TNFa were identical with an
 .IC of 0.54 ngrml Fig. 4c . TGFb had no effect50 2
on Gel A production. Similar inhibition of Gel B
secretion was observed by exposure to TGFb , an1
 .isoform of TGFb data not shown . When C6 cells
 y7 .were treated for 1 h with PMA 10 M before the
addition of TGFb and IL-1a , the inhibitory effect2
Fig. 4. Inhibition by TGFb of gelatinase B secretion. C6 cells were treated at the indicated doses of TGFb for 1 h before the addition of2 2
  .   ..IL-1 100 Urml a or TNFa 100 Urml b . After 18 h, supernatants were collected, lyophilized and assayed for their gelatinase
 .content by zymography. Quantitative analysis were performed by densitometry c . Error bars represent the standard error of the mean of
quadruplicates. Results are representative of three independent experiments.
( )P.-O. Este˝e et al.rBiochimica et Biophysica Acta 1403 1998 85–9692
( )P.-O. Este˝e et al.rBiochimica et Biophysica Acta 1403 1998 85–96 93
 .was reversed by 50% Fig. 5a–b; PF0.05 . PMA
alone had no effect on both gelatinase secretion, but
slightly increased IL-1-stimulated Gel B production.
TGFb acted primarily by downregulating Gel B2
 .gene expression Fig. 6a–b since quantitative den-
sitometric analyses showed that the inhibition by
TGFb on Gel B mRNA levels was comparable2
 .60%; Fig. 6c with that observed by zymography
 .70%; Fig. 4 .
4. Discussion
Several reports have shown that Gel B may play a
crucial role in the development and dissemination of
tumors, including gliomas. In the present work, we
showed that Gel B production, but not that of Gel A,
was closely regulated following stimulation by in-
flammatory cytokines, as IL-1 and TNFa both in-
 .duced de novo Gel B secretion 94 kDa in human
and rat glioma cell lines. In C6 cells, the effect of
IL-1 and TNFa was dose-dependent and additive.
This increased secretion in culture supernatants corre-
lated with an increased expression of Gel B mRNA.
These results imply that expression of Gel A and Gel
B in glioma cells are regulated by distinct signals.
This is consistent with the differences in the promoter
region of Gel A and Gel B genes. More specifically,
Gel A promoter’s gene lacks TATA box and AP-1
binding site, which have been shown to be essential
w xfor the transcription of Gel B gene 20 .
In culture supernatants of both glioma cell lines
tested, Gel A was constitutively found in its activated
form while Gel B was mostly secreted in its proen-
zyme form, suggesting that these two gelatinases
have distinct post-translational regulation. The pres-
ence of the activated form of Gel A in supernatants
of C6 and A172 cell cultures might reflect the pres-
 .ence of membrane-type MMPs MT-MMPs at their
surface. This possibility is supported by in vivo
studies showing a correlation between the expression
and the activation of Gel A and the expression of
MT-MMPs during malignant progression of glioma
w x21 . In turn, Gel A may be responsible for the
generation of minor active forms of Gel B detected in
C6 cell supernatants since proGel B activation can be
w xinduced by Gel A 22 . We cannot, however, exclude
the contribution of others enzymes like stromelysin-1
or serine proteases for the activation of the progelati-
w xnases 23,24 .
As large amount of activated Gel A are available,
especially in the A172 cell line, one could wonder
whether any activation of Gel B would have substan-
tial influence on the total amount of degrading activ-
ity available in the microenvironment around tumor
cells. Although these two MMPs are similar in their
ability to degrade common ECM components, includ-
ing type IV collagen, they do differ markedly in their
overall catalytic efficiency and their substrate speci-
w xficity. For instance, Okada et al. 24 have shown that
Gel B can hydrolyze type IV collagen much more
w xrapidly than Gel A, and Xia et al. 25 demonstrated
that Gel A and Gel B have very different kinetic
profile during cleavage of collagenous peptides. Fur-
 .thermore, binding of procollagenase MMP-1 to type
I collagen is greatly enhanced when collagen films
are first saturated with Gel B, but not when films
w xwere saturated with Gel A 26 . Taken together, these
data suggest that gelatinases A and B may have
different functions in matrix remodeling.
The upregulatory effects of IL-1 and TNFa on Gel
B secretion in C6 cells were inhibited by exposure to
 .TGFb or TGFb . Alone, TGFb had no effect on2 1 2
both gelatinases secretion. These observations are in
contrast with the induction of Gel B production by
 w x.TGFb in others cell types reviewed in Ref. 181
w xand with an earlier report by Merzak et al. 27
showing that TGFb increased the invasion of glioma
cells. Based on these observations one would expect
that the MMP expression would be upregulated in
 y7 .Fig. 5. Reversibility of the TGFb -mediated inhibition of Gel B secretion by PMA. C6 cells were treated with PMA 10 M for 1 h2
 .  .before the addition of TGFb 10 ngrml andror IL-1 100 Urml . After 18 h, supernatants were collected, lyophilized and assayed for2
 .their gelatinase content by zymography. Quantitative analysis were performed by densitometry b . Error bars represent the standard error
of the mean of quadruplicates. Results are representative of three independent experiments. Tukey’s test showed significant differences
between IL-1qTGFb and IL-1qTGFb qPMA. ) PF0.05.2 2
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glioma cells as these enzymes are necessary for ECM
degradation. The apparent contradictory effect of
TGFb on MMP expression may be due to the cell
lines used and the experimental approaches em-
w xployed. Indeed, Paulus et al. 28 demonstrated that
TGFb reduced invasion of U-138MG glioma cells
but had no effect on the invasive behaviour of U-
373MG glioma cell line. Alternatively, the TGFb
inhibitory activity on Gel B secretion is consistent
with its ability to increase collagen biosynthesis by
w xglioma cells 28 , thus favoring ECM deposition
which might create a more permissive environment
w xfor tumor spread into the adjacent brain tissues 29 .
Our data support a model for glioma invasiveness in
two steps. In the first step, an increase of IL-1 or
TNFa activity can induce Gel B production by glioma
cells in the absence of TGFb activity. In a second
step, the cleavage of ECM components by Gel B
w xwould induce the release of TGFb active forms 30 ,
leading to an inhibition of Gel B secretion and the
w xsubsequent ECM deposition 28,31 . This model could
explain in part the remodeling of collagen described
w xby Rucklidge et al. 32 at the glioma invasion zone
in rat brain. Alternatively, one needs to consider the
implication of others MMPs and the effect of TGFb
on their production in C6 cells since Nakano et al.
w x33 demonstrated that TGFb can stimulate produc-
tion of another MMP, matrilysin, in two human
glioma cells.
We demonstrated that the suppressive effect of
TGFb was partially reversed by PMA, an activator2
 . w xof protein kinase C PKC 34 , indicating that the
inhibitory effect of TGFb can act on the PKC2
signaling cascade. PMA alone, however, did not in-
duce Gel B expression in C6 cells, but slightly in-
creased its production when it was added to IL-1.
These data suggest that PKC plays a key role in the
signaling transduction pathway leading to Gel B gene
w xexpression in C6 cells. Kerr et al. 35 have previ-
ously shown that TGFb can inhibit gene expression
of another MMP, transin, in Rat-2 fibroblast cells
through a fos binding sequence, named TIE for
.TGFb inhibitory element . Since Gel B gene expres-
Fig. 6. Inhibition of Gel B gene expression by TGFb . C6 cells2
 6 .  .5=10 cellsrml were stimulated for 18 h with or without NS ,
 .  .TGFb 10 ngrml andror IL-1 100 Urml . Procedures for2
competitive Gel B RT-PCR and b-actin RT-PCR were performed
as described in Section 2. Molecular weight markers are 100 bp
ladder. Densitometry analysis showed Gel BrMIMIC ratio nor-
 .malized for the amount of b-actin RNA analyzed in parallel b .
Results are representative of three independent experiments.
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w xsion is AP-1 dependent 20 and Gel B promoter
w xcontains the TIE sequence 36 , it will be interesting
to determine if this sequence could also mediate the
inhibition of Gel B gene expression in C6 cells.
Several mechanisms are known to be implicated in
tumor invasiveness, for example, cell adhesion to
ECM, motility, degradation of ECM components by
MMPs and the antitumoral response. Expression of
IL-1, TNFa , TGFb and Gel B was found in gliomas
w xin vivo 3,12,19,37 . Our results suggest that the
interplay between these cytokines may play a crucial
role in the regulation of Gel B secretion. Since
infiltrating macrophages and microglial cells are acti-
vated at the border of the invasion zone and can
w xpotentially produce IL-1, TNFa and TGFb 37 , it is
also possible that these immune cells could modulate
invasiveness andror growth of glioma cells by acting
on Gel B secretion. But other factors, like glioma cell
density, could substantially influence their production
w xof collagen type IV degrading activity 38 .
In summary, we showed that IL-1 and TNFa play
a predominant role in the stimulation of Gel B ex-
pression in glioma cells in vitro. The inhibition of
Gel B secretion and gene expression by TGFb illus-2
trates the delicate balance in the local invasive pro-
cess of gliomas by cytokines. The net effect of
TGFb on glioma invasion in vivo remains to be2
determined since TGFb has immunosuppressive ef-
fects and can affect the expression of others MMPs.
Malignant brain tumors, especially glioblastoma mul-
tiforme, cause massive brain tissue destruction,
necrosis and neovascularization in tissues surround-
ing tumor cells. The highly invasive property of brain
tumor is a major obstacle to successful therapy. A
better characterization of the signaling pathways in-
volved in the inhibition of Gel B secretion by TGFb
could provide new therapeutic targets against local
invasiveness of glioma cells.
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